This document assesses the risk associated with the dissemination of carbapenemase-producing hypervirulent Klebsiella pneumoniae (hvKp) of sequence type (ST) 23 and other STs in the European Union/European Economic Area (EU/EEA).
Italy has reported an outbreak of Candida auris in the region of Liguria with at least 277 cases. The first C. auris case in Liguria was detected in one hospital in July 2019 and cases continued to occur sporadically in the same hospital.
Coronavirus disease (COVID-19) outbreaks in long-term care facilities (LTCFs) in European Union and European Economic Area (EU/EEA) countries have caused significant morbidity and mortality since the beginning of the COVID-19 pandemic.
On 14 February 2021, national authorities declared an Ebola virus disease (EVD) outbreak in the rural area of Gouéké in Nzérékoré region, Guinea. As of 18 February 2021, seven EVD cases (three confirmed and four probable) have been identified, including five deaths.
On 7 February 2021, an Ebola virus disease (EVD) outbreak was declared by the Ministry of Health of the Democratic Republic of the Congo (DRC), in the North Kivu province in the eastern part of the country.
This risk assessment details the latest epidemiological data in the European Union/European Economic Area (EU/EEA) and the United Kingdom (UK) with a focus on older age groups and national reports of outbreaks among residents of LTCFs. All EU/EEA countries and the UK have experienced outbreaks among LTCF residents since August 2020.
Carbapenem resistance in Enterobacteriaceae such as Klebsiella pneumoniae and Escherichia coli poses a significant threat to patients and healthcare systems in all European Union/European Economic Area (EU/EEA) countries. Carbapenem-resistant Enterobacteriaceae (CRE) infections are associated with high mortality, primarily due to delays in administration of effective treatment and the limited availability of treatment options.
This is the sixth update of a rapid risk assessment originally produced on 9 August 2018. The update addresses the impact of active chains of Ebola virus disease (EVD) transmission reported outside the outbreak’s epicentre, specifically in Goma, a provincial capital in the Democratic Republic of the Congo (DRC).
This is the fifth update of a rapid risk assessment originally produced on 9 August 2018. This rapid risk assessment addresses the potential public health impact of Ebola virus disease for EU/EEA countries and assesses the likelihood of international expansion.
In 2019, the hajj will take place between 9 and 14 August. The risk for EU/EEA citizens to become infected with communicable diseases during the 2019 hajj is considered low, thanks to the vaccination requirements for travelling to Makkah (Mecca) and the Saudi Arabian preparedness plans that address the management of health hazards during and after hajj.